PF-06480605 is under clinical development by Pfizer and currently in Phase I for Crohn’s Disease (Regional Enteritis). According to GlobalData, Phase I drugs for Crohn’s Disease (Regional Enteritis) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PF-06480605’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PF-06480605 is under development for the treatment of moderate to severe ulcerative colitis. The drug candidate is a fully human immunoglobulin G1 monoclonal antibody, which is administered intravenously and subcutaneously. The drug candidate acts by targeting TNFSF15. It is a new molecular entity. It was also under development for Crohn's disease.
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of PF-06480605’s drug-specific PTSR and LoA scores, buy the report here.